Elekta updates analyst picture, Deutsche Bank trims target on the shares

Deutsche Bank and other houses have refreshed their views on Elekta, with the German bank cutting its price target while keeping a Hold rating. The consensus spread offers retail investors a clearer sense of expectations for the Stockholm-listed medtech group.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 16:11.

Elekta (SE0000163628) sits in focus today with a refreshed analyst landscape around the Stockholm-listed medtech stock. Deutsche Bank has adjusted its view on the shares, offering a concrete benchmark for investors tracking the Nordic medtech peer group against names such as Siemens Healthineers.

What Deutsche Bank signals on Elekta

According to the analyst overview at MarketScreener, Deutsche Bank recently cut its price target for Elekta to 52 Swedish kronor from 60 kronor while reiterating a Hold rating, as noted in the June 22 update.MarketScreener analyst consensus page for Elekta The move reflects a more cautious stance on valuation without shifting the overall recommendation.

The same consensus compilation shows several other houses with neutral to moderately positive views on the stock, with average price targets clustered in a band slightly above the recent share price.Detailed breakdown of Elekta analyst targets and ratings Elekta shares trade on Nasdaq Stockholm, giving the stock a clear anchor in the European medtech sector alongside Philips and Siemens Healthineers.

Consensus picture for the Elekta shares

The MarketScreener consensus for Elekta aggregates recommendations from international houses, showing a spread across Buy, Hold and Sell, with Hold as the dominant stance.Consensus distribution and average target for Elekta The compiled data also indicates an average 12-month price target modestly above current trading levels, pointing to muted upside expectations.

Short-selling statistics on the Stockholm exchange published around June 24 show that Elekta does not feature prominently among the highest aggregated short positions, in contrast to some more volatile names in the Swedish market.MarketScreener note on aggregated short positions at Nasdaq Stockholm For retail investors, the combination of a balanced rating structure and limited short interest suggests a relatively stable sentiment profile for the shares.

How Elekta makes its money

Elekta is a specialist in radiation therapy and radiosurgery solutions for cancer and brain disorders, generating revenue primarily from selling linear accelerators, Gamma Knife systems and associated software and services.Elekta Investor Relations overview of products and segments The company’s portfolio includes the Elekta Unity MR-Linac system, which combines magnetic resonance imaging with radiation delivery to improve precision in cancer treatment.

Where the stock trades today

The Elekta shares (SE0000163628) trade on Nasdaq Stockholm; the latest available data from the Stockholm exchange and common quote services indicates the stock recently changing hands at around 55 Swedish kronor in June 2026, with intraday levels fluctuating modestly around that mark in regular trading.

Key data on the Elekta shares

• Company: Elekta AB
• ISIN: SE0000163628
• WKN: A2N9WW
• Ticker: EKTA B
• Trading venue: Nasdaq Stockholm
• Price (as of 2026-06-24, 16:00): 55.00 SEK
• Market cap: approximately 10 billion SEK (as of 2026-06-24)
• Sector / industry: Health Care / Medical Equipment
• Index membership: Included in Swedish medtech and broader Nordic equity benchmarks
• Next earnings date: not officially scheduled

Disclaimer: This article is for informational purposes only and does not constitute investment advice, tax advice or a solicitation to buy or sell any financial instrument. All data are based on sources believed to be reliable but cannot be guaranteed; investors should conduct their own research or consult a professional adviser before making investment decisions.